Also found in: Wikipedia.


trademark for an intravenous fat emulsion used to prevent or correct deficiency of essential fatty acids and to provide calories in high density form during total parenteral nutrition.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

fat emulsion

(fat ee-mul-shun) ,


(trade name),

Liposyn III

(trade name)


Therapeutic: caloric sources
Pregnancy Category: C


Provision of nonprotein calories to patients whose total caloric needs cannot be met by carbohydrates (glucose) alone, usually as part of parenteral nutrition.Treatment and prevention of essential fatty acid deficiency in patients receiving long-term parenteral nutrition (provides linoleic acid).


Acts as a nonprotein calorie source.

Therapeutic effects

Provision of essential fatty acids and nonprotein calories.


Absorption: IV administration results in complete bioavailability.
Distribution: Distributes into intravascular space.
Metabolism and Excretion: Cleared by conversion to triglycerides, then to free fatty acids and glycerol by lipoprotein lipase. Free fatty acids are transported to tissues, where they may be oxidized as an energy source or re-stored as triglycerides.
Half-life: 30–60 min.

Time/action profile



Contraindicated in: Hyperlipidemias; Lipoid nephrosis; Pancreatitis accompanied by lipemia; Hypersensitivity to egg products (emulsifier is egg yolk phospholipid), legumes, soybeans, or fat emulsions.
Use Cautiously in: Thromboembolic disorders; Severe liver or pulmonary disease; Anemia or bleeding disorders; Patients who are at risk for fat embolism.
Exercise Extreme Caution in: Preterm infants (↓ ability to clear fat emulsion).

Adverse Reactions/Side Effects

Seen only with long-term use.†


  • chest pain


  • intravascular fat accumulation(preterm infants only) (life-threatening)


  • hepatomegaly†
  • jaundice†
  • nausea
  • pancreatitis
  • vomiting


  • phlebitis at IV site (most frequent)


  • hypertriglyceridemia


  • fever (most frequent)
  • infection (most frequent)
  • chills
  • hypersensitivity reactions


Drug-Drug interaction

Concurrent use with propofol may ↑ risk of hypertriglyceridemia.


Total Parenteral Nutrition
Intravenous (Adults) Initial dose: 1 g/kg/day, increase by 0.5–1 g/kg/day to a maximum of 2.5 g/kg/day.
Intravenous (Children ≥1 mo) Initial dose: 0.5–1 g/kg/day, increase by 0.5 g/kg/day to amaximum of 3 g /kg/day.
Intravenous (Neonates premature) Initial dose: 0.25–0.5 g/kg/day, increase by 0.25–0.5 g/kg/day to a maximum of 3 g/kg/day.
Essential Fatty Acid Deficiency
Intravenous (Adults and Children) Provide 8–10% of caloric intake as fat, infuse once or twice weekly.


Emulsion for IV Use: 10%, 20%, 30%

Nursing implications

Nursing assessment

  • Monitor weight every other day in adults and daily in infants and children receiving fat emulsion to assist in meeting caloric requirements.
  • Assess patient for allergy to eggs prior to therapy. Acute hypersensitivity reaction with pruritic urticaria may occur in patients allergic to eggs.
  • Lab Test Considerations: Monitor triglyceride and fatty acid levels routinely to determine patient’s capacity to eliminate infused fat from the circulation. Lipemia must clear between daily infusions.
    • Monitor hemoglobin, blood coagulation, and platelet count weekly, especially during continuous therapy. Report abnormalities promptly. Therapy may be discontinued.
    • Monitor serum bilirubin, cholesterol, and hepatic function weekly, especially in premature infants to prevent hyperlipidemia.
  • If signs of overloading syndrome (focal seizures, fever, leukocytosis, splenomegaly, shock) or elevated triglyceride or free fatty acid levels occur, infusion should be stopped and the patient re-evaluated prior to reinstituting therapy.

Potential Nursing Diagnoses

Imbalanced nutrition: less than body requirements (Indications)
Deficient knowledge, related to medication regimen (Patient/Family Teaching)


  • Intravenous Administration
  • Fat emulsion should comprise no more than 60% of patient’s total caloric intake. The remaining 40% should consist of carbohydrates and amino acids.
    • Fat emulsion may be administered via peripheral or central venous catheter. Monitor peripheral sites for phlebitis.
    • Infuse fat emulsion via Y-site near the infusion site. Because of the lower specific gravity, the fat emulsion solution must be hung higher than the amino acid and dextrose solutions to prevent the fat emulsion from backing up into the amino acid and dextrose line.
    • Manufacturer does not recommend use of filters during administration, but 1.2-micron filters have been used.
    • Use tubing provided by the manufacturer. Change IV tubing after each dose of fat emulsion.
  • Intermittent Infusion: Emulsions that appear oily or that have separated should not be used.30% emulsions must not be infused directly.
    • Pediatric: Avoid use of 10% emulsion in preterm infants; a greater accumulation of plasma lipids occurs due to the greater phospholipid load of the 10% emulsion.
    • Maximum hang times for fat emulsion alone or for admixtures with dextrose and amino acids is 24 hr. Discard all unused portions.
  • Rate: For adults, the initial infusion rate should be 1 mL/min for the 10% solution and 0.5 mL/min for the 20% solution for the first 15–30 min. If no adverse reactions occur, the rate may be increased to infuse 50 mL/hr for the 20% solution or 100 mL/hr for the 10% solution.
    • No more than 500 mL of the 10% solution or 250 mL of 20% solution should be infused at one time.
    • Pediatric: For children, the initial infusion rate should be 0.1 mL/min of the 10% solution and 0.05 mL/min for the 20% solution for the first 10–15 min. If no adverse reactions occur, the rate may be increased to a maximum of 0.25 g/kg/hr.
    • Administer via infusion pump to ensure accurate rate.
  • Y-Site Compatibility: ampicillin, cefazolin, cefoxitin, clindamycin, digoxin, dopamine, erythromycin lactobionate, furosemide, gentamicin, isoproterenol, lidocaine, norepinephrine, oxacillin, penicillin G potassium, tobramycin
  • Y-Site Incompatibility: amikacin
  • Additive Compatibility: Fat emulsion may be admixed (“3-in-1,” all-in-one, triple mix total nutrient admixture [TNA]) or administered simultaneously with amino acid and dextrose solutions, Intralipid is compatible with FreAmine II 8.5%, Travasol without electrolytes 8.5% and 10%, Veinamine 8%, cimetidine, famotidine, hydrocortisone, multivitamins, nizatidine, dextrose 10% and 70%, While not generally recommended, heparin may be added in a concentration of 1–2 units/mL prior to administration to increase clearance rate of lipemia, minimize risks associated with hypercoagulability, and prevent catheter thrombosis
  • Additive Incompatibility: Although compatibility studies have been done, manufacturer recommends that fat emulsion not be admixed with any other medication.

Patient/Family Teaching

  • Explain the purpose of fat emulsion to the patient prior to administration.

Evaluation/Desired Outcomes

  • Weight gain.
    • Maintenance of normal serum triglyceride and fatty acid levels.
Drug Guide, © 2015 Farlex and Partners
References in periodicals archive ?
However, the major current lipid formulation, soy intralipid, has been implicated in cholestasis and liver failure (Colomb et al., 2000).
lower incidence of late onset sepsis and greater weight at 36 weeks before conception with Smoflipid[R] versus Intralipid, in addition to less retinopathy of prematurity (ROP) and greater rates of intraventricular hemorrhage (any grade) with Intralipid.
Zhu, "Emission and absorption properties of indocyanine green in intralipid solution," Journal of Biomedical Optics, vol.
Lipids (Intralipid 20%) were added between day one and two after birth.
Pioglitazone hydrochloride (20 mg/kg) and 3g/kg of 20% intralipid (LIPO MCT injection, Dongkook Pharmaceutical Co., Chungbuk, Korea) were administered via intraperitoneal injection.
(1) Our literature search yielded no studies concerning intralipid therapy for patients with LATS associated with ophthalmic anesthesia, but rapid improvement of LATS symptoms has been demonstrated with 20% IVLE therapy in other surgical settings, both in patients with and without cardiac arrest.
that "it is voluntarily recalling one shipment from a single lot of INTRALIPID 20% IV Fat Emulsion, 100 mL, distributed between 8/11/17 and 8/31/17 to hospitals and healthcare providers in the U.S., to the user level."
Intralipid is a fat emulsion constituting soya bean oil, egg phospholipids and glycerine that has been shown to have immunosuppressive properties (8-9).
The Effect of Intradialytic Intralipid Therapy in Pediatric Hemodialysis Patients.
L., "Diffuse reflectance spectroscopy characterization of hemoglobin and intralipid solutions: in vitro measurements with continuous variation of absorption and scattering", J.